Search
Istradefylline
go.drugbank.com/drugs/DB11757ApprovedInvestigational[L8237] This drug was first approved in Japan on 25 March 2013.[A184067] Istradefylline was granted FDA approval on 27 August 2019.[L8213] … Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy.
Categories: MATE 1 Inhibitors, MATE 2 InhibitorsHydralazine
go.drugbank.com/drugs/DB01275ApprovedInvestigational[A186820,L8782,L8785] Hydralazine is no longer a first line therapy for these indications since the development of newer antihypertensive medications. … [A186841] Hydralazine is a hydrazine derivative vasodilator used alone or as adjunct therapy in the treatment of hypertension and only as adjunct therapy in the treatment of heart failure.
Categories: Arteriolar Smooth Muscle, Agents Acting On, Heterocyclic Compounds, 1-RingSynonyms: 6-Hydralazine, 1-HydrazinophthalazineShort QT syndrome
go.drugbank.com/conditions/DBCOND0022435Drugs: IsoprenalineSynonyms: Genetic short QT syndrome, Genetic short QT syndrome (disorder)V24343
go.drugbank.com/drugs/DB05201InvestigationalThe anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.
Vorinostat
go.drugbank.com/drugs/DB02546ApprovedInvestigationalIt is the first in a new class of agents known as histone deacetylase inhibitors. … A recent study suggested that vorinostat also possesses some activity against recurrent glioblastoma multiforme, resulting in a median overall survival of 5.7 months (compared to 4 - 4.4 months in earlier
Products: ZOLINZA®VORINOSTAT 100 MG CAPSULASCongenital neutropenia
go.drugbank.com/conditions/DBCOND0020521Drugs: FilgrastimSynonyms: Infantile genetic agranulocytosis, Severe infantile genetic neutropeniaManganese gluconate
go.drugbank.com/drugs/DB11141ApprovedManganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.
Mixtures: Cal-mag Plus K, Mn and Zn Caplets, Vitamin E 400 Iu With Selenium, Vitamin C & ManganeseSynonyms: Manganese D-gluconate, Manganese(II) gluconateEmpagliflozin
go.drugbank.com/drugs/DB09038ApprovedInvestigationalEmpagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart … Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney.
Synonyms: (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol, 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzeneMixtures: GLYXAMBI® 25 MG/ 5 MG, GLYXAMBI® 10 MG/ 5 MGMirvetuximab soravtansine
go.drugbank.com/drugs/DB12489ApprovedInvestigationalThis decision was supported by findings from the phase 3 SORAYA trial (NCT04296890).[L43967,L43972] It was subsequently granted full approval in March 2024. … [L50306] In October 2024, it was approved in the EU for the same indication. [L52640]
Categories: P-glycoprotein substrates, Cytochrome P-450 SubstratesDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma … All the work around duvelisib showed that this agent is a potent inhibitor of both forms.[A39025] Duvelisib was developed by Verastem, Inc and FDA approved on September 24, 2018.[L4585]
Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates